Ronald I. Meltzer
Director/Board Member at Sequella, Inc.
Profile
Ronald I.
Meltzer is currently a Director at Sequella, Inc. and a Member-Washington Leadership Board at State University of New York at Buffalo Law School.
He formerly worked as a Principal at American University and as a Professor at State University of New York at Buffalo.
He holds a doctorate degree from The Trustees of Columbia University in The City of New York, a graduate degree from New York University, and an undergraduate degree from The Ohio University.
Ronald I. Meltzer active positions
Companies | Position | Start |
---|---|---|
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | Director/Board Member | - |
State University of New York at Buffalo Law School | Corporate Officer/Principal | 20/07/2011 |
Former positions of Ronald I. Meltzer
Companies | Position | End |
---|---|---|
American University | Corporate Officer/Principal | - |
State University of New York at Buffalo | Corporate Officer/Principal | - |
Training of Ronald I. Meltzer
New York University | Graduate Degree |
The Trustees of Columbia University in The City of New York | Doctorate Degree |
The Ohio University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Sequella, Inc.
Sequella, Inc. Pharmaceuticals: MajorHealth Technology Sequella, Inc. develops antibiotic drugs resistant to bacterial, fungal, and parasitic infections. It offers product for Mycobacterium tuberculosis, Helicobacter pylori, Clostridium difficile, Nontuberculous mycobacteria, Trypanosomes, and fungal infections. The company was founded by Carol A. Nacy and Leo Einck in 1997 and is headquartered in Rockville, MD. | Health Technology |
- Stock Market
- Insiders
- Ronald I. Meltzer